Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360 · see citing works

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · see citing works

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091 · see citing works

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

Grewal, I. S., & Flavell, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.111 · Cited by 1,538 · see citing works

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355 · see citing works

Cancer despite immunosurveillance: immunoselection and immunosubversion

Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · see citing works

Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice

Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., MALISSEN, B., Zinkernagel, R. M., & Hengartner, H. (1991) · Cell · doi:10.1016/0092-8674(91)90164-t · Cited by 1,170 · see citing works

The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells

Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,042 · see citing works

Redefining Chronic Viral Infection

Virgin, H. W., Wherry, E. J., & Ahmed, R. (2009) · Cell · doi:10.1016/j.cell.2009.06.036 · Cited by 1,031 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

CD40/CD154 Interactions at the Interface of Tolerance and Immunity

Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104533 · Cited by 685 · see citing works

Chapter 8 Use of Recombinant Adenovirus for Metabolic Engineering of Mammalian Cells

Becker, T. C., Noel, R. J., Coats, W. S., Gómèz‐Foix, A. M., Alam, T., Gerard, R. D., & Newgard, C. B. (1994) · Methods in cell biology · doi:10.1016/s0091-679x(08)60603-2 · Cited by 569 · see citing works

CD8 ⁺ T‐cell memory in tumor immunology and immunotherapy

Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · see citing works

The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class Switching

Rolink, A. G., Melchers, F., & Andersson, J. (1996) · Immunity · doi:10.1016/s1074-7613(00)80258-7 · Cited by 404 · see citing works

Twelve immunotherapy drugs that could cure cancers

Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 339 · see citing works

CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M. W., Der, S. D., Kang, J., & Chambers, C. A. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266 · see citing works

The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors.

Janik, P., Briand, P., & Hartmann, N. R. (1975) · PubMed · Cited by 217 · see citing works

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

Advani, R. H., Forero, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K. L., Whiting, N. C., & Drachman, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3017 · Cited by 188 · see citing works

Cytotoxic T-Lymphocyte–Associated Antigen-4

Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 148 · see citing works

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

Gregor, P. D., Wolchok, J. D., Ferrone, C. R., Buchinshky, H., Guevara-Patino, J. A., Perales, M., Mortazavi, F., Bacich, D. J., Heston, W., Latouche, J., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.10.048 · Cited by 124 · see citing works

Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-α induction pathway

Philpott, N. J., Nociari, M., Elkon, K. B., & Falck-Pedersen, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308368101 · Cited by 118 · see citing works

Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections

Ha, S., West, E. E., Araki, K., Smith, K. A., & Ahmed, R. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00638.x · Cited by 90 · see citing works

Role of MyD88 and TLR9 in the Innate Immune Response Elicited by Serotype 5 Adenoviral Vectors

Yamaguchi, T., Kawabata, K., Koizumi, N., Sakurai, F., Kaneda‐Nakashima, K., Sakurai, H., Sasaki, T., Okada, N., Yamanishi, K., & Mizuguchi, H. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.016 · Cited by 87 · see citing works

MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines

Holst, P. J., Sørensen, M. R., Jensen, C. M. M., Ørskov, C., Thomsen, A. R., & Christensen, J. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3339 · Cited by 87 · see citing works

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

Ahonen, C. L., Wasiuk, A., Fuse, S., Turk, M. J., Ernstoff, M. S., Suriawinata, A. A., Gorham, J. D., Kedl, R. M., Usherwood, E. J., & Noelle, R. J. (2008) · Blood · doi:10.1182/blood-2007-09-114371 · Cited by 86 · see citing works

Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors

Schjetne, K. W., Fredriksen, A. B., & Bogen, B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4169 · Cited by 69 · see citing works

Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance

den Boer, A. T., Diehl, L., van Mierlo, G. J. D., van der Voort, E. I. H., Fransen, M. F., Krimpenfort, P., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2522 · Cited by 69 · see citing works

Cytotoxic T-Lymphocyte–Associated Antigen-4

Hodi, F. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0813 · Cited by 63 · see citing works

Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies

Gray, J. C., French, R. R., James, S., Al‐Shamkhani, A., Johnson, P., & Glennie, M. J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838208 · Cited by 54 · see citing works

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4

Pedersen, A. E., Buus, S., & Claësson, M. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.012 · Cited by 53 · see citing works

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4+ T‐cell‐independent CD8+ T‐cell‐mediated tumor control

Sørensen, M. R., Holst, P. J., Pircher, H., Christensen, J. P., & Thomsen, A. R. (2009) · European Journal of Immunology · doi:10.1002/eji.200939543 · Cited by 52 · see citing works

The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling

Met, Ö., Wang, M., Pedersen, A. E., Nissen, M. H., Buus, S., & Claësson, M. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.02.005 · Cited by 51 · see citing works

Suppression of Mature Dendritic Cell Function by Regulatory T Cells In Vivo Is Abrogated by CD40 Licensing

Hänig, J., & Lutz, M. B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1405 · Cited by 51 · see citing works

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

Welters, M. J. P., Bijker, M. S., van den Eeden, S. J. F., Franken, K. L. M. C., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.049 · Cited by 51 · see citing works

Deficient CD4+ T Cell Priming and Regression of CD8+ T Cell Functionality in Virus-Infected Mice Lacking a Normal B Cell Compartment

Christensen, J. P., Kauffmann, S. Ø., & Thomsen, A. R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4733 · Cited by 45 · see citing works

Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas

Sanchez-Perez, L. A., Kottke, T. J., Daniels, G. A., Díaz, R. M., Thompson, J., Pulido, J. S., Melcher, A. A., & Vile, R. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.4168 · Cited by 44 · see citing works

Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma

Liu, Y., Xia, D., Li, F., Zheng, C., & Xiang, J. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700757 · Cited by 25 · see citing works

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

Weber, J. S. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232292.06785.a3 · Cited by 18 · see citing works

Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma

Hussein, M. A., Berenson, J. R., Niesvizky, R., Munshi, N. C., Anderson, K. C., Ryan, K. L., Baumgartner, K. T., Miller, D. M., Drachman, J. G., & McDonald, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.6581 · Cited by 7 · see citing works

Virus‐based immunotherapy of cancer: what do we know and where are we going?

Sørensen, M. R., & Thomsen, A. R. (2007) · Apmis · doi:10.1111/j.1600-0643.2007.00802.x · Cited by 4 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

Turning the corner on therapeutic cancer vaccines

Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689 · see citing works

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335 · see citing works

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy

Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236 · see citing works

T cell exhaustion: from pathophysiological basics to tumor immunotherapy

Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

Rajani, K. R., Parrish, C., Kottke, T. J., Thompson, J., Zaidi, S., Ilett, E. J., Shim, K. G., Díaz, R. M., Pandha, H., Harrington, K. J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.156 · Cited by 188 · see citing works

Whole Cell Vaccines—Past Progress and Future Strategies

Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167 · see citing works

Armed oncolytic viruses: A kick-start for anti-tumor immunity

de Graaf, J. F., de Vor, L., Fouchier, R. A. M., & van den Hoogen, B. G. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.03.006 · Cited by 147 · see citing works

CTLA-4 correlates with immune and clinical characteristics of glioma

Liu, F., Huang, J., Liu, X., Cheng, Q., Luo, C., & Liu, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1085-6 · Cited by 115 · see citing works

CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies

Bullock, T. N. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00734-4 · Cited by 110 · see citing works

Therapeutic cancer vaccine: building the future from lessons of the past

Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 83 · see citing works

Oncolytic Adenoviruses for Cancer Immunotherapy

Cerullo, V., Koski, A., Vähä-Koskela, M. J. V., & Hemminki, A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00008-2 · Cited by 76 · see citing works

CTLA-4 blockade and the renaissance of cancer immunotherapy

D, S. M. M., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 71 · see citing works

Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non–Self-Tumor Antigens: Implications for Cancer Immunotherapy

Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P., & Thomsen, A. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300555 · Cited by 72 · see citing works

The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer

Khong, A., Nelson, D. J., Nowak, A. K., Lake, R., & Robinson, B. W. S. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.698338 · Cited by 67 · see citing works

Concepts for agonistic targeting of CD40 in immuno-oncology

Richards, D. M., Sefrin, J. P., Gieffers, C., Hill, O., & Merz, C. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1653744 · Cited by 68 · see citing works

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 67 · see citing works

Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

Ottaviano, M., Placido, S. D., & Ascierto, P. A. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02538-4 · Cited by 62 · see citing works

Nanomaterials‐Mediated Co‐Stimulation of Toll‐Like Receptors and CD40 for Antitumor Immunity

Yan, J., Zhang, Y., Du, S., Hou, X., Li, W., Zeng, C., Zhang, C., Cheng, J. K. J., Deng, B., McComb, D. W., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207486 · Cited by 60 · see citing works

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence

Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 58 · see citing works

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

Zamarin, D., & Wolchok, J. D. (2014) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2014.4 · Cited by 44 · see citing works

Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma

Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 43 · see citing works

Self-assembling peptides as immunomodulatory biomaterials

Hernández, A., Hartgerink, J. D., & Young, S. W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1139782 · Cited by 39 · see citing works

Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies

Abdou, Y. G., Pandey, M. R., Sarma, M., Shah, S., Baron, J. I., & Ernstoff, M. S. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14316 · Cited by 35 · see citing works

Checkpoint blockade in combination with cancer vaccines

Morse, M. A., & Lyerly, H. K. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.057 · Cited by 34 · see citing works

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

Yano, H., Thakur, A. B., Tomaszewski, E. N., Choi, M., Deol, A., & Lum, L. G. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-191 · Cited by 32 · see citing works

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells

Merz, C., Sykora, J., Marschall, V., Richards, D. M., Heinonen, K., Müller, M. R., Thiemann, M., Schnyder, T., Fricke, H., Hill, O., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000246 · Cited by 32 · see citing works

Coinhibitory molecules in cancer biology and therapy

D, S. M. M., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 27 · see citing works

Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T‐cell activation

Wälchli, S., Kumari, S., Fallang, L.-E., Sand, K. M. K., Yang, W., Landsverk, O. J. B., Bakke, O., Olweus, J., & Gregers, T. F. (2013) · European Journal of Immunology · doi:10.1002/eji.201343671 · Cited by 25 · see citing works

Cancer Vaccines: Recent Insights and Future Directions

Malacopol, A.-T., & Holst, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011256 · Cited by 24 · see citing works

An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression

Ragonnaud, E., Andersson, A.-M. C., Pedersen, A. E., Laursen, H., & Holst, P. J. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.06.087 · Cited by 23 · see citing works

Adenovirus-Based Immunotherapy of Cancer: Promises to Keep

de Gruijl, T. D., & van de Ven, R. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00006-9 · Cited by 18 · see citing works

The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies

Jensen, B. A. H., Pedersen, S. R., Christensen, J. P., & Thomsen, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066081 · Cited by 16 · see citing works

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma

Morandi, F., Frassoni, F., Ponzoni, M., & Brignole, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/8097398 · Cited by 16 · see citing works

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma

Zhang, Y., Wu, X., Sharma, A., Weiher, H., Schmid, M. C., Kristiansen, G., & Schmidt‐Wolf, I. G. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925633 · Cited by 15 · see citing works

Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review

Ghaneialvar, H., Jahani, S., Hashemi, E., Khalilzad, M. A., Falahi, S., Rashidi, M. A., Majidpoor, J., & Najafi, S. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111209 · Cited by 14 · see citing works

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Hernandez, R., & Malek, T. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878377 · Cited by 15 · see citing works

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

D’Alise, A. M., Nocchi, L., Garzia, I., Seclì, L., Infante, L., Troise, F., Cotugno, G., Allocca, S., Romano, G., Lahm, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156714 · Cited by 14 · see citing works

Immune correlates of melanoma survival in adoptive cell therapy

Fermin, A., Sieling, P. A., & Lee, D. J. (2013) · OncoImmunology · doi:10.4161/onci.22889 · Cited by 13 · see citing works

Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience

Ramirez, A. G., Wages, N. A., Hu, Y., Smolkin, M. E., & Slingluff, C. L. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1758-5 · Cited by 13 · see citing works

Harnessing Immune Checkpoints for Cancer Therapy

Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 13 · see citing works

CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells

Navarrete, A., Delignat, S., Teillaud, J., Kaveri, S. V., Lacroix‐Desmazes, S., & Bayry, J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.095 · Cited by 10 · see citing works

Breadth of T Cell Responses After Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens

Ragonnaud, E., Pedersen, A. G., & Holst, P. J. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12522 · Cited by 10 · see citing works

Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status

Zhang, Y., & Liu, Z. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191104090544 · Cited by 9 · see citing works

Current advances in kidney cancer immunotherapy

Коротаева, А. А., Apanovich, N. V., Александровна, Б. Э., Matveev, V. B., & Karpukhin, A. V. (2019) · Cancer Urology · doi:10.17650/1726-9776-2019-15-4-30-38 · Cited by 7 · see citing works

The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence

Ragonnaud, E., & Holst, P. J. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613480446 · Cited by 7 · see citing works

Co-Expression of Tumor Antigen and Interleukin-2 From an Adenoviral Vector Augments the Efficiency of Therapeutic Tumor Vaccination

Jensen, B. A. H., Steffensen, M. A., Nielsen, K. N., Christensen, J. P., Thomsen, A. R., & Holst, P. J. (2014) · Molecular Therapy · doi:10.1038/mt.2014.130 · Cited by 7 · see citing works

The human‐specific invariant chain isoform Iip35 modulates Iip33 trafficking and function

Sand, K. M. K., Landsverk, O. J. B., Berg‐Larsen, A., Bakke, O., & Gregers, T. F. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.54 · Cited by 5 · see citing works

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Wu, Y., & Song, H. X. (2022) · Life · doi:10.3390/life12010130 · Cited by 3 · see citing works

Overcoming Cancer Tolerance with Immune Checkpoint Blockade

Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2 · see citing works

Induction of B cl‐x L ‐Specific Cytotoxic T Lymphocytes in Mice

Larsen, H. L., Andersen, M. H., Wandall, H. H., Madsen, C. B., Christensen, R. E., Petersen, T. R., & Pedersen, A. E. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12192 · Cited by 2 · see citing works

Nanoparticle-Based Specific Targeting of Antigen-Presenting Cells for Immunotherapy

Lindstedt, M., & Broos, S. (2014) · Nanomedicine and nanotoxicology · doi:10.1007/978-4-431-55139-3_13

Perancangan Aplikasi Sistem Pakar Untuk Diagnosis Penyakit Ginjal Dengan Kombinasi Metode Certainty Factor Dan Metode Forward Chaining

Silalahi, R. (2011)

Overcoming Cancer Tolerance with Immune Checkpoint Blockade

Myers, J. W., Peoples, G. E., & Clifton, G. T. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_6

Targeting VISTA as a novel immunotherapy for skin cancer

Hou, Y., Chen, X., & Chen, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1815113

High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome

Grinshtein, N., Ventresca, M. S., Margl, R., Bernard, D., Yang, T.-C., Millar, J. B. A., Hummel, J., Beermann, F., Wan, Y., & Bramson, J. L. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.89 · Cited by 29 · see citing works

Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients

McGray, A. R., Bernard, D., Hallett, R. M., Kelly, R., Jha, M., Gregory, C., Bassett, J. D., Hassell, J. A., Paré, G., Wan, Y., et al. (2012) · OncoImmunology · doi:10.4161/onci.19534 · Cited by 28 · see citing works

Immunotherapy for murine K1735 melanoma: Combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators

Peter, I. S., Nawrath, M., Kamarashev, J. A., Odermatt, B., Mezzacasa, A., & Hemmi, S. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700475 · Cited by 23 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied

Depigmentation, A., van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999)

Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.

Kikuchi, T., Miyazawa, N., Moore, M. A., & Crystal, R. G. (2000) · PubMed · Cited by 66 · see citing works